State coverage
Michigan Medicaid and GLP-1 coverage
Medicaid, for obesity: Covers for weight loss. The conditions and the appeal deadline are in the summary below.
At a glance
- Medicaid, for obesity
- Coverage survived January 1, 2026, but only for morbid obesity after every other treatment has failed.
- Appeal deadline
- 90 days from the written notice of case action source
- Primary source
- Michigan Department of Health and Human Services
- Date read
- August 2026
Michigan is the state that shows why counting states is the wrong way to read this. It did not end coverage, so every tally still lists it as covering. What it did on January 1, 2026 was rewrite the conditions hard enough that the listing and the reality have drifted apart.
The trigger was budget legislation, Public Act 22 of 2025, and the state's letter to providers says plainly that coverage "will be reduced." Three requirements arrived with it: you must be classified as morbidly obese, every other clinically appropriate weight-loss treatment must have been tried and documented as failed, and your prescriber has to attest that the drug is being used to avert the need for bariatric surgery. That last one is not a clinical threshold at all. It reframes the drug as the cheaper alternative to an operation.
So Michigan covers these drugs. Whether you get through the gate is a separate question from whether the state pays, and the criteria below are the ones your prescriber will have to answer.
What we could verify for Michigan
Michigan reduced this coverage on January 1, 2026 under Public Act 22 of 2025, the budget legislation. The state's letter to providers says coverage of GLP-1 medications "when prescribed solely to treat obesity, including requests for continuation, will be reduced," while coverage for other indications "will not be changing." It sets three new requirements: the patient "must be classified as morbidly obese"; coverage is "contingent on documented failure of all other clinically appropriate weight-loss interventions"; and it is available "only as a measure to avert the need for higher-cost bariatric surgery."
Michigan Department of Health and Human Services, effective January 2026 · source
The criteria document puts numbers on it. For adults, the prescriber attests to "an initial body mass index (BMI) classified as morbidly obese (e.g., baseline BMI ≥ 40 kg/m2 or greater)." Before that, there must be trial and failure with all five types of preferred non-GLP-1 agents — the document names benzphetamine, diethylpropion, orlistat products, phendimetrazine and phentermine — or a contraindication or unacceptable side effects across all five.
Michigan Department of Health and Human Services, effective September 2026 · source
Approval runs six months at a time, initial and renewal alike, and keeping it requires results: the prescriber must document "that the patient has maintained a weight loss of ≥ 5% from baseline weight at initiation of therapy." There is also a separate, tighter gate for people who started before the rules changed — at first renewal they must be shown to have met the new morbid-obesity, failed-interventions and avert-surgery tests as of when they began.
Michigan Department of Health and Human Services, effective September 2026 · source
Your health plan cannot be stricter than this. Michigan requires its Medicaid Health Plans to follow the same drug list the fee-for-service program uses: "Effective for dates of service on or after October 1, 2020, [MDHHS] Policy Bulletin 20-51 ... will require Medicaid Health Plans (MHPs) to follow the Michigan PDL used by the Fee-for-Service (FFS) pharmacy program. This will be described as the Single PDL."
Michigan Department of Health and Human Services, effective August 2026 · source
If you are refused, Michigan's manual says a denial of prior authorization is one of the decisions you can appeal, and that "the client or AHR has 90 calendar days from the date of the written notice of case action to request a hearing," with the request needing to reach the local office inside those 90 days. If you are in a managed care plan you must finish that plan's internal appeal first before you can ask the state for a hearing.
Michigan Department of Health and Human Services, Bridges Administrative Manual 600, effective May 2026 · source
Michigan is one of 10 states whose Medicaid gives the same answer: pay for these drugs for weight loss, with prior authorization. Michigan Medicaid's rule doesn't reach a job-based plan or Medicare. If you have one of those, read employer plans or Medicare Part D instead, and compare Michigan with the rest in the coverage matrix.
Regional insurers that sell plans in Michigan and have their own page here, quoted from their own policy documents: Blue Cross Blue Shield of Michigan. The national insurers are on the insurance index.
If you work for the State of Michigan
State employees aren't on Medicaid, so the answer above isn't yours. Your plan is the one the state buys for its workers: State Health Plan PPO and State HDHP. Its pharmacy benefit runs through Optum Rx.
Weight loss and sleep apnea excluded since January 2026
Michigan stopped covering Saxenda, Wegovy and Zepbound for weight management and sleep apnea on January 1, 2026. They stay covered for diabetes and heart diagnoses, and the state's two HMO options don't cover them for weight either.
"Effective January 1, 2026, GLP-1 inhibitors (e.g., Saxenda, Wegovy, and Zepbound) will no longer be covered under the SHP PPO and State HDHP for weight management or sleep apnea but will continue to be covered for diabetes management and cardiovascular diagnoses."
Michigan Civil Service Commission, 2026 State of Michigan Employee Benefits Open Enrollment, effective October 2025 · source
"All existing prior authorization approvals for GLP-1 inhibitors with a weight management or sleep apnea diagnosis will end effective December 31, 2025."
Michigan Civil Service Commission, 2026 State of Michigan Employee Benefits Open Enrollment, effective October 2025 · source
"Neither Blue Care Network (BCN) nor Health Alliance Plan (HAP) cover GLP-1 inhibitors for weight management."
Michigan Civil Service Commission, 2026 State of Michigan Employee Benefits Open Enrollment, effective October 2025 · source
"When preauthorized by Blue Cross, benefits are available for non-medical weight reduction up to a lifetime maximum of $300."
Blue Cross Blue Shield of Michigan, Your Benefit Guide, State Health Plan PPO (2026), effective January 2026 · source
If the appeal fails, or you cannot wait
Michigan Medicaid pays for these drugs for weight loss with prior authorization, so a denial there is worth appealing before anything else. If the appeal fails, or you can't wait for it, cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself.
These companies pay us a commission if you start care through the links below. That is how this site is funded, and it does not change what is written above. How we pay for this.
| Company | What we found on its own site |
|---|---|
| PartnerShedRxCheck availability | Injections plus needle-free drops and lozenges. You see a price only after the questionnaire, and the oral forms aren't sold in sixteen states. |
| PartnerHealthRXCheck availability | Compounded semaglutide at $133 a month on a three-month plan ($99 on twelve), tirzepatide from $209 ($179 on twelve). Its member reviews are labeled illustrative composites, not real patients. |
| PartnerMEDGmCheck availability | GLP-1 injections from $179 and tablets from $249. Brand options are a membership plus the drug's own cost: $99 for Zepbound or Wegovy, $171 for Ozempic. It discloses AI content and actor imagery. |
| PartnerBodybuilding Health+Check availability | Compounded tirzepatide at $174.67 to $209 a month, lower the more months you buy at once; semaglutide is tiered the same way. Operated by Dynamo Group LLC. |
| PartnerStrut HealthCheck availability | A telehealth storefront where weight loss is one of six categories. No GLP-1 price is published on the page our link opens. |
| PartnerRxSpan MDCheck availability | Multi-category telehealth that promises transparent pricing, then publishes no GLP-1 price on the page our link opens. |
All 21 companies, with what we found on each →
Prices in those notes were read from each company's own site in September 2026, and they change often. Check the current number before you buy.
Where this comes from
- Michigan Department of Health and Human Services, effective January 2026 — www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/Assistance-Program
- Michigan Department of Health and Human Services, effective September 2026 — www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/MHP-Common-Formula
- Michigan Department of Health and Human Services, effective August 2026 — www.michigan.gov/mdhhs/-/media/Project/Websites/mdhhs/State-of-Michigan-
- Michigan Department of Health and Human Services, Bridges Administrative Manual 600, effective May 2026 — mdhhs-pres-prod.michigan.gov/olmweb/EX/BP/Public/BAM/600.pdf